

Directions for Use of Varicella Vaccine, Live

Name of the vaccine
Varicella Vaccine, Live

Compositions and Form

The vaccine is made by propagation of live attenuated varicella-zoster virus (Oka strain) in human diploid cell culture (MRC-5), after cultivation and harvest, the virus suspension is lyophilized to make the vaccine after addition of a suitable stabilizer. This product is white fluff pellet in the glass vial. The reconstituted vaccine after dissolution with diluent is a clear solution without visually detectable presence of foreign particles.

Active ingredient: Live attenuated varicella-zoster virus (Oka strain); not less than 3.3 Log PFU
Excipients: 22.5 mg Trehalose, 5 mg Human Albumin, 4.5 mg Sodium Glutamate, 3.8 mg Sucrose, 1.85 mg Glucose, 0.9 mg Urea, 0.9 mg Arginine.
Diluent: 0.5 mL Sterile Water for Injection

Therapeutic indications

The vaccine is indicated for the active immunization against varicella of healthy, varicella-susceptible subjects from age of 12 months to 50 years.

Specification

The vial contains 0.5 mL liquid by dissolution of the lyophilized vaccine with the diluent. The dissolution vaccine contains not less than 3.3 Log PFU of live attenuated varicella-zoster virus and is used for one subject in a single dose.

Immune procedures and dosage

- (1) One dose of immunization for infants and children of 12 months to 12 years old; two doses of immunization for people of 13 years old and above with 4-8 weeks of interval.
- (2) Transfer the entire diluent with a syringe into the vial containing lyophilized vaccine. Shake well to ensure complete dissolution of the pellet for use and transfer all the liquid back to the syringe.
- (3) Apply 0.5 mL suspension for subcutaneous injection at the deltoid area of the upper arm.
- (4) Alcohol and any other disinfectant may inactivate the attenuated virus, thus the vaccination should be applied right after ensuring the complete evaporation of the disinfectant away from skin.

Undesirable side effects
Clinical Studies

Adverse events are ranked under headings of frequency using the following convention: very common ($\geq 10\%$); common ($\geq 1\%$ and $< 10\%$); occasional ($\geq 0.1\%$ and $< 1\%$); rare ($\geq 0.01\%$ and $< 0.1\%$); very rare ($< 0.01\%$).

Events reported in infants and children of 12 months to 12 years old

In a clinical trial involving 600 infants and children of 12 months to 12 years old immunized by the product.

Systemic reaction

Very common: fever $\geq 37.1^{\circ}\text{C}$;
Common: headache, diarrhea, rash, cough, crying;
Occasional: malaise, weakness, myalgia, erythema, drowsiness and anorexia.

Local reaction

Very common: pruritus, redness, swelling, and pain.

Events reported in people of 13 years old and above

In a clinical trial involving 928 people of 13 years old and above immunized by the product.

Local and systemic reaction

Very common: fever $\geq 37.1^{\circ}\text{C}$;
Common: headache, weakness, reddened on injection site, pain, swelling, pruritus;
Occasional: allergic reaction, rash, induration.

Reaction for gastrointestinal system

Common: anorexia.

Contraindications

- (1) Subjects with known hypersensitivity to any constituent of this product including neomycin.
- (2) Women during pregnancy.
- (3) Subjects suffering from serious diseases (acute or chronic infection), fever and any advanced immune disease.
- (4) Subjects treated with steroid drug.
- (5) Subjects with a total lymphocyte count of less than 1200 per mm^3 or presenting other signs of cellular immunodeficiency.

- (6) Subjects with known history of congenital immune disease or having closely touched with the family member who has a history of this disease.
- (7) The effects of this product will be cut down for use of whole blood, plasma or immunoglobulin within 5 months before vaccination or within 3 weeks after vaccination.
- (8) Avoid the use of salicylate within 5 weeks following vaccination of this product.

Special precautions

- (1) It is advisable to have a solution of epinephrine available in case of rare anaphylactic reaction.
- (2) Generally speaking, it is advisable to keep the subject under medical supervision for 30 minutes following vaccination of this product.
- (3) Transmission of vaccine virus only occurs in extremely rare cases. All patients who may develop varicella, especially the patients suffering from cutaneous reaction two to three weeks after vaccination, should avoid contacting with patients suffering from leukemia or who are undergoing immune-suppressant therapy, or pregnant women especially in the first three months of pregnancy.
- (4) Administered subcutaneously, not intradermally and never, under any circumstances, intravenously.
- (5) Avoid any disinfectant to contact the vaccine of this product during opening the vaccine vials and carrying the injection. Alcohol and any other disinfectants may inactivate the attenuated virus, thus the vaccination should be applied right after ensuring the complete evaporation of the disinfectant away from skin.
- (6) Not allow to administer injection in conditions of incomplete dissolution of this product, foreign matters observed in the dissolved vaccine, cracked glass vial and unclear label of glass vial.

- (7) Women of child-bearing age can be vaccinated only if appropriately contraceptive measures have been taken for at least 3 months following vaccination.
- (8) Vaccine of this product should be administered immediately when opening the vaccine vials; in special circumstances, the vaccine can be placed at $2-8^{\circ}\text{C}$, and should be used within 30 minutes, the remaining vaccine should be discarded.
- (9) Administration of other live attenuated vaccine should keep at least one-month interval after vaccination with this vaccine of product; however, this vaccine of product can be administered simultaneously with live attenuated vaccines of measles, rubella and mumps.
- (10) Patients suffering from leucocythemia, tumor or immunodeficiency should be restrained use under doctors' guidance.
- (11) Patients in the following conditions should be restrained use: person or the person's family has convulsions history, patients suffering from chronic disease, history of epilepsy, patients with allergic constitution, women in lactation.
- (12) Patients injected with immunoglobulin should administer this vaccine of product at least after 3-month interval to avoid influencing the immunization effects.

Pharmacological properties

Non clinical studies in mice and guinea pig showed that live attenuated varicella vaccine did not result toxic and hypersensitive effects. In a clinical study involving 600 infants and children of 1-12 years old, 1 dose of Varicella Vaccine live produced by Changchun BCHT Biotechnology Co., can increase immunogenicity with seroconversion rates of above 90%. The immune response of Varicella Vaccine, Live in infants is similar with the one in children. The immune response of Varicella Vaccine, Live is higher in naive subjects. The immunogenicity profile of Varicella Vaccine, Live is similar with the approved vaccine. Immunogenicity data can be seen in the below table.

Efficacy following vaccination between test group and control group

| Group | Sub-Group | Negative in pre-immunization | | | | Positive in pre-immunization | | Total | | 95%CI | |
|---------------|-------------|------------------------------|-------------------------|-------|----|------------------------------|-------|----------------|-----|--------|-------------|
| | | n | Positive Seroconversion | n | % | Four Times Boost | n | Total Positive | | | |
| | | | | | | | | n | % | | |
| Test group | Infant (T1) | 147 | 147 | 100.0 | 23 | 22 | 95.65 | 170 | 169 | 99.41 | 96.77-99.99 |
| | Child (T2) | 114 | 113 | 99.12 | 71 | 67 | 94.37 | 185 | 180 | 97.30 | 93.81-99.21 |
| | Sum (T) | 261 | 260 | 99.62 | 94 | 89 | 94.68 | 355 | 349 | 98.31 | 96.36-99.38 |
| | | | | | | | | | | | |
| Control group | Infant (C1) | 72 | 72 | 100.0 | 11 | 11 | 100.0 | 83 | 83 | 100.00 | 96.46-100 |
| | Child (C2) | 56 | 56 | 100.0 | 34 | 33 | 100.0 | 90 | 89 | 98.89 | 93.96-99.97 |
| | Sum (C) | 128 | 128 | 100.0 | 45 | 44 | 97.78 | 173 | 172 | 99.42 | 96.62-99.99 |
| | | | | | | | | | | | |

In clinical study involving 928 people aged of 13 years old and above showed that the positive rate of antibody in the experimental group and the control group was 87.65% and 88.38% after immunization with one dose, and 96.70% and 95.55% after immunization with two doses respectively, similar to the summary and reference materials in the test manual. Immunogenicity data can be seen in the below table.

Efficacy following vaccination between test group and control group

| Group | Sub-Group | Dose | Negative in pre-immunisation | | Positive in pre-immunisation | | Total | | 95%CI | | | |
|---------------|--------------------|--------------|------------------------------|--------------------|------------------------------|---------------------|-------|----------------|-------|------|-------|-------------|
| | | | n | Positive Serone | n | Four Times Boost | n | Total Positive | | | | |
| | | | | | | | | | | n | % | n |
| Test group | 13-16 years of age | After 1 dose | 198 | 168 | 84.85 | 286 | 238 | 83.22 | 484 | 406 | 83.88 | 79.08-89.54 |
| | | After 2 dose | 198 | 196 | 98.99 | 286 | 274 | 95.80 | 484 | 470 | 97.11 | 96.40-99.88 |
| | 17-50 years old | After 1 dose | 265 | 245 | 92.09 | 289 | 266 | 92.04 | 554 | 511 | 92.24 | 88.58-95.33 |
| | | After 2 dose | 265 | 260 | 92.45 | 289 | 282 | 97.58 | 554 | 542 | 97.83 | 95.65-99.38 |
| Control group | Sum | After 1 dose | 463 | 413 | 88.11 | 575 | 504 | 87.65 | 1038 | 917 | 88.34 | 86.01-91.88 |
| | | After 2 dose | 463 | 456 | 89.49 | 575 | 556 | 96.70 | 1038 | 1012 | 97.50 | 96.91-99.39 |
| | 13-16 years of age | After 1 dose | 106 | 97 | 91.51 | 144 | 126 | 87.50 | 250 | 223 | 89.20 | 84.49-96.04 |
| | | After 2 dose | 106 | 104 | 98.11 | 144 | 133 | 92.36 | 250 | 237 | 94.80 | 93.35-99.77 |
| Control group | 17-50 years old | After 1 dose | 132 | 122 | 92.42 | 148 | 135 | 91.22 | 280 | 257 | 91.79 | 86.51-96.31 |
| | | After 2 dose | 132 | 131 | 99.24 | 148 | 145 | 98.65 | 280 | 277 | 98.93 | 95.85-99.98 |
| | Sum | After 1 dose | 238 | 219 | 92.02 | 292 | 261 | 89.38 | 530 | 480 | 90.57 | 87.81-93.13 |
| | | After 2 dose | 238 | 235 | 98.74 | 292 | 279 | 95.55 | 530 | 514 | 96.98 | 96.36-99.74 |

Storage

Stored in a refrigerator and transported with cold chain in dark between $2-8^{\circ}\text{C}$. Do not freeze.

Presentation

Registered packaging in Indonesia
Box, 1 vial vaccine @ 1 dose + 1 vial diluent 0.5 mL

Validity period

36 months.
Hasur dengan reseap dokter
Reg. No.: DK1746100144A1

Manufactured by

Changchun BCHT Biotechnology Co.
1260 Huojia Road, Changchun High-tech Zone, Changchun, Jilin 130012, China.

Imported by

PT. Bio Farma (Persero)
Jl. Pasteur No. 28
Bandung, Indonesia.

Pada proses pembuatannya bersinggungan dengan bahan bersumber babi.

DISETUJUI OLEH BPOM 3 AGUSTUS 2021

ID REG : EREG10040912000173



環球印務
GLOBAL PRINTING
ARTWORK
报告单 / REPORT
www.globalprinting.cn

订单ID: SMYY001436-1-
盒型: 说明书
尺寸(mm): 160 × 150mm
刀版编号: /
销售负责: 张强
工艺负责: 刘晓庆
制作负责: 刘晓庆
输出日期: 20210802 10:57:06
文件名称: SMYY001436-1_z_v4

顾客名称: 长春百克生物科技股份公司
产品名称: 水痘减毒活疫苗(印尼两针剂)说明书
请您在确认稿件内容无误后签字确认
☐ 颜色 ☐ 文字 ☐ 版式 ☐ 成品尺寸 ☐ 条形码
顾客签字/日期:

04
No.

Informasi Produk untuk Pasien Varicella Vaccine, Live

Nama Vaksin

Varicella Vaccine, Live

Komposisi dan bentuk

Varicella Vaccine, Live dibuat dengan mengembangbiakan virus varicella-zoster hidup yang dilemahkan (strain Oka) pada kultur human diploid cell (MRC-5). Setelah proses kultivasi dan pemanenan, dilakukan liofilisasi terhadap suspensi virus yang telah ditambahkan penstabil yang sesuai.

Produk ini berwarna putih berbentuk pellet di dalam vial kaca. Vaksin yang telah direkonstitusi dengan pelarut, berbentuk larutan bening yang bebas dari partikel asing.

Zat aktif : Virus varicella-zoster hidup yang dilemahkan (strain Oka), tidak kurang dari 3,3 Log PFU.

Eksipien : 22,5 mg Trehalosa; 5 mg Human albumin; 4,5 mg Sodium glutamate; 3,8 mg Sukrosa; 1,85 mg Glukosa; 0,9 mg Urea; 0,9 mg Arginin
Pelarut: 0,5 mL Sterile Water for Injection

Indikasi Terapeutik

Vaksin diindikasikan untuk pencegahan terhadap varicella pada mereka yang sehat, rentan terhadap varicella mulai dari usia 12 bulan hingga 50 tahun.

Spesifikasi

Vial berisi cairan 0,5 mL dari vaksin beku-kering yang dilarutkan dengan pelarut. Vaksin yang sudah dilarutkan mengandung tidak kurang dari 3.3 Log PFU virus varicella-zoster hidup yang dilemahkan dan digunakan untuk satu subjek dalam dosis tunggal.

Dosis dan Cara Penggunaan

(1) Satu dosis imunisasi pada bayi dan anak usia 12 bulan hingga 12 tahun atau dua dosis imunisasi pada individu usia 13 tahun keatas dengan interval 4-8 minggu.

(2) Masukkan seluruh pelarut menggunakan syringe ke dalam vial yang berisi vaksin beku-kering. Kocok dengan baik untuk memastikan pelet larut sempurna sebelum digunakan. Ambil kembali vaksin yang sudah dilarutkan tersebut menggunakan syringe.

(3) Injeksikan 0,5 mL vaksin secara subkutan di area deltoid lengan atas.

(4) Alkohol dan disinfektan lainnya dapat menginaktivasi virus hidup yang dilemahkan, sehingga vaksinasi harus dilakukan dengan benar, setelah memastikan disinfektan menguap sempurna dari permukaan kulit.

Efek Samping yang Tidak Diinginkan

Studi Klinik

Efek samping diurutkan berdasarkan frekuensinya sebagai berikut : sangat umum ($\geq 10\%$); umum ($\geq 1\%$ dan $<10\%$); sesekali ($\geq 0,1\%$ dan $<1\%$); jarang ($\geq 0,01\%$ dan $<0,1\%$); sangat jarang ($<0,01\%$).

Kejadian yang dilaporkan terjadi pada bayi dan anak usia 12 bulan hingga 12 tahun

Uji klinis melibatkan 600 bayi dan anak-anak 1-12 tahun yang diimunisasi dengan produk ini.

Reaksi sistemik

Sangat umum : demam $\geq 37,1^{\circ}\text{C}$;

Umum : sakit kepala, diare, ruam, batuk, menngis;

Sesekali : lemas, mual, nyeri otot, eretisme, mengantuk, dan anoreksia.

Reaksi lokal

Sangat umum : gatal, kemerahan, bengkak, dan nyeri

Kejadian yang dilaporkan terjadi pada individu usia 13 tahun keatas

Uji klinis melibatkan 928 orang usia 13 tahun keatas yang diimunisasi dengan produk ini.

Reaksi lokal dan sistemik

Sangat umum : demam $\geq 37,1^{\circ}\text{C}$;

Umum : sakit kepala, lemas, kemerahan pada tempat suntikan, nyeri, bengkak, gatal;

Sesekali : reaksi alergi, ruam, indurasi.

Reaksi pada sistem pencernaan

Umum : anoreksia (kehilangan nafsu makan)

Kontraindikasi

(1) Subjek yang diketahui memiliki hipersensitivitas terhadap komposisi vaksin termasuk neomisin.

(2) Wanita hamil.

(3) Subjek yang sedang menderita penyakit serius (infeksi akut atau kronis), demam dan penyakit imun berat.

(4) Subjek dalam pengobatan dengan obat steroid.

(5) Subjek dengan jumlah total limfosit kurang dari 1200 per mm^3 atau menunjukkan tanda-tanda lain dari imunodefisiensi selular.

(6) Subjek dengan riwayat penyakit imun bawaan atau kontak erat dengan anggota keluarga yang memiliki riwayat penyakit imun.

(7) Efek dari produk ini akan menurun jika menggunakan produk darah, plasma atau immunoglobulin selama 5 bulan sebelum vaksinasi atau selama 3 minggu setelah vaksinasi.

(8) Hindari penggunaan salisilat selama 6 minggu setelah diimunisasi dengan produk ini.

Perhatian Khusus

(1) Dianjurkan untuk menyediakan larutan epinefrin jika terjadi reaksi anafilaksis.

(2) Secara umum, disarankan untuk melakukan pengawasan medis kepada subjek selama 30 menit setelah vaksinasi produk ini.

(3) Penularan virus vaksin merupakan kasus yang sangat jarang terjadi. Hindari kontak dengan pasien yang mungkin menderita varicella, terutama pasien yang menderita reaksi kulit dua hingga tiga minggu setelah vaksinasi, harus menghindari kontak dengan pasien yang menderita leukemia atau yang sedang menjalani terapi imunosupresan, atau wanita hamil terutama dalam tiga bulan pertama kehamilan.

(4) Diberikan secara subkutan, tidak secara intradermal dan dalam kondisi apapun jangan diberikan secara intravena.

(5) Hindari kontak desinfektan dengan vaksin ketika membuka vial vaksin dan ketika melakukan injeksi.

(6) Dilarang melakukan injeksi dalam kondisi vaksin tidak larut sempurna, partikel asing teramat dalam vaksin terlarut, kaca vial retak dan label vial tidak jelas.

(7) Wanita usia subur dapat divaksinasi hanya jika tindakan kontrasepsi yang tepat telah diambil setidaknya 3 bulan setelah vaksinasi.

(8) Gunakan segera setelah vaksin dibuka; pada keadaan khusus, vaksin dapat disimpan pada suhu $2-8^{\circ}\text{C}$ dan digunakan dalam 30 menit. Sisa vaksin harus dimusnahkan.

(9) Pemberian vaksin hidup yang dilemahkan lainnya harus diberikan jarak setidaknya satu bulan setelah pemberian vaksin ini. Namun, Varicella Vaccine, Live ini dapat diberikan bersamaan dengan vaksin measles, rubella, dan mumps hidup yang dilemahkan.

(10) Pasien dengan leukositemia, tumor atau imunodefisiensi harus dalam pengawasan dokter

(11) Penggunaan perlu dikendalikan pada individu dengan kondisi berikut : individu/keluarga memiliki riwayat kejang, pasien penyakit kronis, memiliki riwayat epilepsi, alergi komponen vaksin, dan wanita menyusui.

(12) Individu yang mendapatkan immunoglobulin perlu diberi jarak minimal 3 bulan jika akan menggunakan vaksin ini untuk menghindari pengaruh terhadap efek imunisasi.

Penyimpanan

Disimpan dalam lemari pendingin dan diangkut dengan cold chain, terlindung dari cahaya pada suhu antara $2-8^{\circ}\text{C}$. Jangan dibekukan.

Kemasan

Kemasan terdaftar di Indonesia:

Dus, 1 Vial vaksin @ 1 dosis + 1 vial pelarut 0,5 mL.

Shelf life

36 bulan

Harus dengan resep dokter

Reg. No.: DK11746100144A1

Diproduksi Oleh

Changchun BCHT Biotechnology Co.

1260 Huoju Road, Changchun High-tech Zone, Changchun. Jilin 130012, China.

Diimpor Oleh

PT. Bio Farma (Persero)

Jl. Pasteur No. 28

Bandung, Indonesia.

Pada proses pembuatannya bersinggungan dengan bahan bersumber babi.

DISETUJUI OLEH BPOM 3 AGUSTUS 2021

ID REG : EREG10040912000173



ARTWORK
报告单 / REPORT

www.globalprinting.cn

订单ID: SMYY001436-1-
盒型: 说明书
尺寸(mm): 160 × 150mm
刀版编号: /
销售负责: 张强
工艺员: 刘晓庆
制作者: 刘晓庆
输出日期: 20210719 16:09:06
文件名称: SMYY001436-1_b_V3

顾客名称: 长春百克生物科技股份有限公司
产品名称: 水痘减毒活疫苗(印尼两针剂)说明书

请您在确认稿件内容无误后签字确认

☐ 颜色 ☐ 文字 ☐ 版式 ☐ 成品尺寸 ☐ 条形码

顾客签字/日期:

03
No.